These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38254778)

  • 21. Evaluation of a Gene Expression Profiling Assay in Primary Cutaneous Melanoma.
    Kangas-Dick AW; Greenbaum A; Gall V; Groisberg R; Mehnert J; Chen C; Moore DF; Berger AC; Koshenkov V
    Ann Surg Oncol; 2021 Aug; 28(8):4582-4589. PubMed ID: 33486642
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Attitudes of patients with cutaneous melanoma toward prognostic testing using the 31-gene expression profile test.
    Ahmed K; Siegel JJ; Morgan-Linnell SK; LiPira K
    Cancer Med; 2023 Jan; 12(2):2008-2015. PubMed ID: 35915969
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integrating the 40-Gene Expression Profile (40-GEP) Test Improves Metastatic Risk-Stratification Within Clinically Relevant Subgroups of High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients.
    Wysong A; Somani AK; Ibrahim SF; Cañueto J; Fitzgerald AL; Siegel JJ; Prasai A; Goldberg MS; Farberg AS; Regula C; Bar A; Kasprzak J; Brodland DG; Koyfman SA; Arron ST
    Dermatol Ther (Heidelb); 2024 Mar; 14(3):593-612. PubMed ID: 38424384
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative Metastatic Rates in GEP Class 1A versus 1B Posterior Uveal Melanoma: Results Contrary to Expectations.
    Augsburger JJ; Skinner CC; Correa ZM
    Ocul Oncol Pathol; 2023 Feb; 8(4-6):242-249. PubMed ID: 36925732
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular risk prediction in cutaneous melanoma: A meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients.
    Greenhaw BN; Covington KR; Kurley SJ; Yeniay Y; Cao NA; Plasseraud KM; Cook RW; Hsueh EC; Gastman BR; Wei ML
    J Am Acad Dermatol; 2020 Sep; 83(3):745-753. PubMed ID: 32229276
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between traditional clinical high-risk features and gene expression profile classification in uveal melanoma.
    Nguyen BT; Kim RS; Bretana ME; Kegley E; Schefler AC
    Graefes Arch Clin Exp Ophthalmol; 2018 Feb; 256(2):421-427. PubMed ID: 29185101
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship between clinical features, GEP class, and PRAME expression in uveal melanoma.
    Schefler AC; Koca E; Bernicker EH; Correa ZM
    Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1541-1545. PubMed ID: 31065847
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Integrating the melanoma 31-gene expression profile test with clinical and pathologic features can provide personalized precision estimates for sentinel lymph node positivity: an independent performance cohort.
    Kriza C; Martin B; Bailey CN; Bennett J
    World J Surg Oncol; 2024 Aug; 22(1):228. PubMed ID: 39215342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Integration of a 31-Gene Expression Profile Into Clinical Decision-Making in the Treatment of Cutaneous Melanoma.
    Scott AM; Dale PS; Conforti A; Gibbs JN
    Am Surg; 2020 Nov; 86(11):1561-1564. PubMed ID: 32755379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrating 40-GEP Testing to Improve Clinical Recommendations for Adjuvant Radiation for Cutaneous Squamous Cell Carcinoma: Multidisciplinary Consensus Guidelines.
    Gopal R; Marquardt M; Singh G; Tolkachjov SN; Arron ST
    J Clin Aesthet Dermatol; 2024 Mar; 17(3 Suppl 2):S3-S8. PubMed ID: 38495846
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of stage I/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP).
    Amaral T; Sinnberg T; Chatziioannou E; Niessner H; Leiter U; Keim U; Forschner A; Dwarkasing J; Tjien-Fooh F; Wever R; Flatz L; Eggermont A; Forchhammer S
    Eur J Cancer; 2023 Mar; 182():155-162. PubMed ID: 36739215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Using a Clinicopathologic and Gene Expression (CP-GEP) Model to Identify Stage I-II Melanoma Patients at Risk of Disease Relapse.
    Mulder EEAP; Johansson I; Grünhagen DJ; Tempel D; Rentroia-Pacheco B; Dwarkasing JT; Verver D; Mooyaart AL; van der Veldt AAM; Wakkee M; Nijsten TEC; Verhoef C; Mattsson J; Ny L; Hollestein LM; Olofsson Bagge R
    Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740520
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Performance of Gene Expression Profile Tests for Prognosis in Patients With Localized Cutaneous Melanoma: A Systematic Review and Meta-analysis.
    Marchetti MA; Coit DG; Dusza SW; Yu A; McLean L; Hu Y; Nanda JK; Matsoukas K; Mancebo SE; Bartlett EK
    JAMA Dermatol; 2020 Sep; 156(9):953-962. PubMed ID: 32745161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Utility of a 31-gene expression profile for predicting outcomes in patients with primary cutaneous melanoma referred for sentinel node biopsy.
    Arnot SP; Han G; Fortino J; Han D; Fowler G; Vetto JT
    Am J Surg; 2021 Jun; 221(6):1195-1199. PubMed ID: 33773750
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Prognostic Gene Signature Expressed in Primary Cutaneous Melanoma: Synergism With Conventional Staging.
    Brunner G; Heinecke A; Falk TM; Ertas B; Blödorn-Schlicht N; Schulze HJ; Suter L; Atzpodien J; Berking C
    JNCI Cancer Spectr; 2018 Jul; 2(3):pky032. PubMed ID: 31360859
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Validation of the Prognostic Usefulness of the Gene Expression Profiling Test in Patients with Uveal Melanoma.
    Miguez S; Lee RY; Chan AX; Demkowicz PC; Jones BSCL; Long CP; Abramson DH; Bosenberg M; Sznol M; Kluger H; Goldbaum MH; Francis JH; Pointdujour-Lim R; Bakhoum MF
    Ophthalmology; 2023 Jun; 130(6):598-607. PubMed ID: 36739981
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 31-GEP (DecisionDx): a review of clinical utility and performance in a Mayo Clinic cohort.
    Pazhava A; Kim YH; Jing FZ; Pittelkow MR
    Int J Dermatol; 2024 Aug; ():. PubMed ID: 39154363
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Integrating gene expression profiling into NCCN high-risk cutaneous squamous cell carcinoma management recommendations: impact on patient management.
    Farberg AS; Hall MA; Douglas L; Covington KR; Kurley SJ; Cook RW; Dinehart SM
    Curr Med Res Opin; 2020 Aug; 36(8):1301-1307. PubMed ID: 32351136
    [No Abstract]   [Full Text] [Related]  

  • 39. Impact of Gene Expression Profiling on Decision-Making in Clinically Node Negative Melanoma Patients after Surgical Staging.
    Schuitevoerder D; Heath M; Cook RW; Covington KR; Fortino J; Leachman S; Vetto JT
    J Drugs Dermatol; 2018 Feb; 17(2):196-199. PubMed ID: 29462228
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improved Prognostic Precision in Uveal Melanoma through a Combined Score of Clinical Stage and Molecular Prognostication.
    Stacey AW; Dedania VS; Materin M; Demirci H
    Ocul Oncol Pathol; 2022 Feb; 8(1):35-41. PubMed ID: 35356606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.